Trending Stock News

Achillion Pharmaceuticals, Inc. (ACHN) Reaches $3.01 52-Week Low; Citizens & Northern Decreased Gilead Sciences (GILD) Stake

The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) hit a new 52-week low and has $2.77 target or 8.00% below today’s $3.01 share price. The 8 months bearish chart indicates high risk for the $414.95M company. The 1-year low was reported on Dec, 1 by Barchart.com. If the $2.77 price target is reached, the company will be worth $33.20M less. The stock decreased 3.53% or $0.11 during the last trading session, reaching $3.01. About 1.81M shares traded. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 47.61% since December 1, 2016 and is downtrending. It has underperformed by 64.31% the S&P500.

Citizens & Northern Corp decreased Gilead Sciences Inc (GILD) stake by 38.48% reported in 2017Q2 SEC filing. Citizens & Northern Corp sold 6,199 shares as Gilead Sciences Inc (GILD)’s stock declined 8.05%. The Citizens & Northern Corp holds 9,910 shares with $701,000 value, down from 16,109 last quarter. Gilead Sciences Inc now has $97.50B valuation. The stock decreased 0.19% or $0.14 during the last trading session, reaching $74.64. About 3.92 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since December 1, 2016 and is downtrending. It has underperformed by 38.50% the S&P500.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on February, 6. They expect $1.67 EPS, down 36.74% or $0.97 from last year’s $2.64 per share. GILD’s profit will be $2.18 billion for 11.17 P/E if the $1.67 EPS becomes a reality. After $2.23 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -25.11% negative EPS growth.

Investors sentiment increased to 0.93 in Q2 2017. Its up 0.02, from 0.91 in 2017Q1. It increased, as 78 investors sold GILD shares while 538 reduced holdings. 110 funds opened positions while 462 raised stakes. 938.32 million shares or 0.11% more from 937.32 million shares in 2017Q1 were reported. Peak Asset Mngmt Lc accumulated 80,821 shares. New York-based Tiaa Cref Limited Liability has invested 0.31% in Gilead Sciences, Inc. (NASDAQ:GILD). Noesis Mangement stated it has 103,748 shares. Beck Mack Oliver Limited Liability Corp, a New York-based fund reported 393,591 shares. Temasek (Private) Limited, Singapore-based fund reported 11.13M shares. St Germain D J owns 4,006 shares. Walleye Trading Ltd Limited Liability Company stated it has 0.02% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). First Interstate Financial Bank has 1.64% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 111,973 shares. Glg Ltd invested in 0.3% or 68,920 shares. Alphamark Advsrs Ltd Co has invested 0% in Gilead Sciences, Inc. (NASDAQ:GILD). 7,572 were accumulated by Denver Inv Advsrs Limited Liability Corporation. Hl Services Limited Co reported 60,321 shares. Pekin Singer Strauss Asset Mngmt Il invested 0.17% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Chevy Chase Trust Holdings has invested 0.38% in Gilead Sciences, Inc. (NASDAQ:GILD). Berson & Corrado Inv Advsr Ltd Liability accumulated 1.98% or 50,966 shares.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 19 have Buy rating, 0 Sell and 11 Hold. Therefore 63% are positive. Gilead Sciences had 107 analyst reports since July 29, 2015 according to SRatingsIntel. The stock has “Buy” rating by Mizuho on Thursday, September 28. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Buy” rating by William Blair on Wednesday, June 14. The firm earned “Hold” rating on Friday, July 21 by BMO Capital Markets. As per Tuesday, July 25, the company rating was maintained by Mizuho. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Outperform” rating by RBC Capital Markets on Monday, October 3. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Buy” rating by RBC Capital Markets on Wednesday, October 4. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Buy” rating by Stifel Nicolaus on Monday, November 14. Piper Jaffray maintained the stock with “Overweight” rating in Friday, July 24 report. RBC Capital Markets maintained the shares of GILD in report on Wednesday, November 2 with “Outperform” rating. Piper Jaffray maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Wednesday, February 3. Piper Jaffray has “Overweight” rating and $114 target.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. The company has market cap of $414.95 million. The Company’s drug candidates for treating chronic hepatitis C virus infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. It currently has negative earnings. The firm is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors.

Analysts await Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to report earnings on February, 22. They expect $-0.15 EPS, down 400.00% or $0.12 from last year’s $-0.03 per share. After $-0.14 actual EPS reported by Achillion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 7.14% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *